Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001316480 | SCV001507104 | uncertain significance | Developmental and epileptic encephalopathy 94 | 2020-02-24 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C25"). This variant has not been reported in the literature in individuals with CHD2-related disease. This variant is present in population databases (rs760795656, ExAC 0.003%). This sequence change replaces valine with alanine at codon 186 of the CHD2 protein (p.Val186Ala). The valine residue is highly conserved and there is a small physicochemical difference between valine and alanine. |
Genome |
RCV001316480 | SCV001749330 | not provided | Developmental and epileptic encephalopathy 94 | no assertion provided | phenotyping only | Variant interpreted as Uncertain significance and reported on 04-16-2018 by Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. |